3499cc拉斯维加斯(官网VIP入口)-The best platform

Risen Pharma
A clinical stage group with innovative drug research and development capability and international competitiveness
Committed to clinical urgent, patient accessible drug R&D and commercialization. The Group has two R&D centers (with a total square footage of nearly 9000m²), which are located in the hub of Shanghai Zhangjiang Hi-Tech Park and Suzhou Industrial Park, and invested in the construction of a manufacturing site covering 55 acres of land in the Life Blue Bay of Lingang,. The Group has nearly 20 new drug research and development pipelines, focusing on drug R&D in the three core therapeutic areas of orthopedics, oncology and neuroscience, and dedicated R&D investment in the field of siRNA.
Risen Pharma
A clinical stage group with innovative drug research and development capability and international competitiveness
Committed to clinical urgent, patient accessible drug R&D and commercialization. The Group has two R&D centers (with a total square footage of nearly 9000m²), which are located in the hub of Shanghai Zhangjiang Hi-Tech Park and Suzhou Industrial Park, and invested in the construction of a manufacturing site covering 55 acres of land in the Life Blue Bay of Lingang,. The Group has nearly 20 new drug research and development pipelines, focusing on drug R&D in the three core therapeutic areas of orthopedics, oncology and neuroscience, and dedicated R&D investment in the field of siRNA.
Corporate Culture
People-centered
To serve the patients, Risen built a team as the driving force for innovation. With the strong support of investors, together with partners and suppliers, we are committed to providing doctors with diversified therapeutics to benefit human beings.
Team
Doctor
Investor
Partners
Supplier
Patient
Accept Challenges Pursue Excellence Persist in innovation Technological innovation first R&D efficiency first People development first
Development History
2015
2019
2020
2021
2022
2023
2015.07

Incorporation of the Company

2015.08

Series A Funding - RMB 53.6 million

2015.12

Suzhou Lab Opens

2019.02

Risen-TopAlliance Cooperation - RMB 300 million

2019.07

Executives from Orthopedics and Clinical Medicine Join.

2019.10

Suzhou Lab Undergoes Two Expansions

2020.05

Executives from Drug Development and Pharmaceutical Chemistry Join.

2020.07

RP903 FDA P-IND

2020.12

RP901 CDE IND

2020.12

B Round Funding - RMB 374 Million

2021.03

RP901 Clinical Phase I SAD

2021.09

Acquisition of 56 mu of land in Lingang Area

2021.10

RP902 CDE P-IND

2021.12

RP903 CDE P-IND

2021.12

RP901 FDA IND

2022.03

RP903 CDE IND

2022.05

RP901 临床I期 MAD

2022.06

RP904 CDE P-IND

2022.06

RP903 FDA IND

2022.06

首席科学官CSO、生物高管加入

2022.06

张江研发中心竣工

2023.2

First in China: ANGPTL3 siRNA drug
clinical trial

2023.2

RP904 tablets have obtained approval for clinical trials from the NMPA.

2023.3

Risen was entitled as a "special and innovative" small to medium-sized

Management Team
Jiasheng Lv, Ph.D.
Founder、CEO
Xiangsheng Ye, Ph.D.
CSO
Xianqi Kong, Ph.D.
Senior Vice President
Tianlun Zhou, Ph.D.
Vice President, Biology
Dawei Chen, Ph.D.
Vice President,Chemistry
mei-shu.shih, Ph.D.
Vice President,Orthopedics and Pathology.
Ji Jiang, Ph.D.
Vice President,Clinical Medicine
Emma Saffman, Ph.D.
Vice President,IP
Partners
The joint R&D of small molecule drugs by TopAlliance and Risen in the field of anti-tumor therapy complements the small molecule anti-tumor drug development pipeline of TopAlliance, while conducive to the exploration of Mab drug combination therapy in the future.
Jiasheng Lv, Ph.D.
Founder、CEO
With nearly 15 years of drug research experience, Dr. Lv has led a number of Class 1 innovative drug projects and is an inventor of several clinical drug compounds. Among them, the new drug project for Alzheimer's disease is in phase III clinical research in the United States (orphan drug, fast-track approval); He served as a professor at the Beijing Institute of Technology and led a number of national key projects. He is also a visiting professor of Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences.
Xiangsheng Ye, Ph.D.
CSO
With 25 years of drug R&D and more than 10 years of translational medicine platform building and management experience, Dr. Ye served as the head of Oncology Research at Lilly China/Asia, where he led the development of drugs targeting cancer cell cycles and major cancer signaling pathways, including the successful launch of abemaciclib, the best-in-class CDK4/6 inhibitor. He is currently a professor at the Shenzhen Research Institute of Tsinghua University.
Xianqi Kong, Ph.D.
Senior Vice President
With nearly 30 years of drug research and development experience, hundreds of international patents, Dr. Kong has wealth of intellectual property application, protection experience. He previously served as Director of Pharmacy at Bellus Health Inc. (TSX:BLU), a publicly traded Canadian biotechnology company, and was the first inventor of several clinical experimental compounds.
Tianlun Zhou, Ph.D.
Vice President, Biology
With nearly 30 years of drug research and development experience, especially in RNA drugs and anti-HBV drug R&D, Dr. Zhou is proficient in medicine, cancer epidemiology, molecular biology, data mining and pathway analysis and other fields. He was previously head of antiviral drug development and translational cancer research at Novartis.
Dawei Chen, Ph.D.
Vice President,Chemistry
Dr. Chen has been engaged in the research and development of small molecule drugs for nearly 20 years, and discovered a number of clinical compounds in antiviral, immune system diseases and anti-tumor areas. He served as principal scientist at Achillion Pharmaceuticals (Nasdaq:ACHN), a publicly traded pharmaceutical company in US.
mei-shu.shih, Ph.D.
Vice President,Orthopedics and Pathology.
30多年药物研发经验,国际骨科及病理资深专家;曾担任多家美国知名医药机构研发总监,前澎立生物医药技术(上海)有限公司首席科学家,主持超过60个国内外新药申报项目。
Ji Jiang, Ph.D.
Vice President,Clinical Medicine
近30年新药临床医学研究经验,国内著名临床研究专家;曾担任北京协和医院核医学研究院教授和临床药理中心主任,作为主要研究者承担100余项药物I期临床试验、进口和仿制药等效性研究。
Emma Saffman, Ph.D.
Vice President,IP
超过20年的北美知识产权保护工作经验,有深厚的医药领域专业知识,对北美专利的申请、评估以及专利的国际化管理和商业化运用有着丰富的经验;曾担任加拿大上市公司Bellus Health Inc. (TSX:BLU) 知识产权总监。
Shanghai Zhangjiang R&D Center.
Suzhou Industrial Park R&D Center.
Shanghai Lingang Industrial Base.
send mail
Copyright 2022 Risen(Shanghai) Pharma Tech Co., Ltd. All Rights Reserved 沪ICP备16020731号-1 Design by:yushangweb